{"id":"lbvh0101-hib-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, redness, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability"},{"rate":null,"effect":"Drowsiness"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains purified Hib polyribosyl ribitol phosphate (PRP) polysaccharide conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent immune response. This allows the vaccine to induce both humoral and cellular immunity, providing protection against invasive Hib disease including meningitis, bacteremia, and epiglottitis.","oneSentence":"LBVH0101 is a Haemophilus influenzae type b (Hib) conjugate vaccine that stimulates the immune system to produce antibodies against Hib polysaccharide capsule.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:22.787Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive Haemophilus influenzae type b disease (meningitis, bacteremia, epiglottitis)"}]},"trialDetails":[{"nctId":"NCT01251133","phase":"PHASE3","title":"Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2008-07","conditions":"Infectious Disease by Haemophilus Influenzae Type b","enrollment":122},{"nctId":"NCT01019772","phase":"PHASE3","title":"Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of Age","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2007-07","conditions":"Infectious Disease by Haemophilus Influenzae Type b","enrollment":217}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LBVH0101 (Hib vaccine)","genericName":"LBVH0101 (Hib vaccine)","companyName":"LG Life Sciences","companyId":"lg-life-sciences","modality":"Biologic","firstApprovalDate":"","aiSummary":"LBVH0101 is a Haemophilus influenzae type b (Hib) conjugate vaccine that stimulates the immune system to produce antibodies against Hib polysaccharide capsule. Used for Prevention of invasive Haemophilus influenzae type b disease (meningitis, bacteremia, epiglottitis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}